Zhejiang Ausun Pharmaceutical Co Ltd
SSE:603229
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
6.59
16.58
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Zhejiang Ausun Pharmaceutical Co Ltd stock under the Base Case scenario is 9.66 CNY. Compared to the current market price of 6.59 CNY, Zhejiang Ausun Pharmaceutical Co Ltd is Undervalued by 32%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Zhejiang Ausun Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling Zhejiang Ausun Pharmaceutical Co Ltd based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Zhejiang Ausun Pharmaceutical Co Ltd
Balance Sheet Decomposition
Zhejiang Ausun Pharmaceutical Co Ltd
Current Assets | 1.7B |
Cash & Short-Term Investments | 966.3m |
Receivables | 346.6m |
Other Current Assets | 391.4m |
Non-Current Assets | 1.3B |
Long-Term Investments | 69.6m |
PP&E | 1.1B |
Intangibles | 148.9m |
Current Liabilities | 622.6m |
Accounts Payable | 250.2m |
Accrued Liabilities | 26.2m |
Short-Term Debt | 331.4m |
Other Current Liabilities | 14.9m |
Non-Current Liabilities | 36.6m |
Long-Term Debt | 2.1m |
Other Non-Current Liabilities | 34.5m |
Earnings Waterfall
Zhejiang Ausun Pharmaceutical Co Ltd
Revenue
|
840.4m
CNY
|
Cost of Revenue
|
-376.1m
CNY
|
Gross Profit
|
464.3m
CNY
|
Operating Expenses
|
-166m
CNY
|
Operating Income
|
298.4m
CNY
|
Other Expenses
|
-24.8m
CNY
|
Net Income
|
273.5m
CNY
|
Free Cash Flow Analysis
Zhejiang Ausun Pharmaceutical Co Ltd
CNY | |
Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
Zhejiang Ausun Pharmaceutical Co Ltd's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Zhejiang Ausun Pharmaceutical Co Ltd's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Zhejiang Ausun Pharmaceutical Co Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Zhejiang Ausun Pharmaceutical Co Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Zhejiang Ausun Pharmaceutical Co Ltd
Shareholder Yield
Current shareholder yield for Zhejiang Ausun Pharmaceutical Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Price
Zhejiang Ausun Pharmaceutical Co Ltd
Average Annual Return | 53.35% |
Standard Deviation of Annual Returns | 65.72% |
Max Drawdown | -89% |
Market Capitalization | 5.5B CNY |
Shares Outstanding | 830 297 000 |
Percentage of Shares Shorted |
N/A
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the manufacture, sale, research and development of pharmaceutical intermediates and raw materials. The company is headquartered in Taizhou, Zhejiang and currently employs 846 full-time employees. The company went IPO on 2017-05-09. The firm's main products include bimatoprost, latanoprost, latanoprostene bunod, entecavir, selectfluor and other intermediates. The firm is also involved in the provision of customized production, as well as research and development services to customers through its subsidiaries.
Contact
IPO
Employees
Officers
The intrinsic value of one Zhejiang Ausun Pharmaceutical Co Ltd stock under the Base Case scenario is 9.66 CNY.
Compared to the current market price of 6.59 CNY, Zhejiang Ausun Pharmaceutical Co Ltd is Undervalued by 32%.